Look about right?
Date Brokerage Action Rating Price Target
7/3/19 Oppenheimer Init Cov Outperform $15.00 Matthew Biegler
7/23/19 Roth Capital Init Cov Buy $10.00 Tony Butler
3/29/19 WBB upgrade Strong buy $12.50 Steve Brozak
?? Janney upgrade $15.00 Yun Zhong
12/3/18 Piper Jaffray Upgrade overweight $10 Edward Tenthoff
11/21/18 Nomura Init Cov Buy $16.00 Christopher Marai
"Looking ahead, Tony Butler also said there’s a 70% chance the company’s therapy will win government approval followed by commercialization during 2024. After the launch we assume relatively rapid uptake with competitive peak penetrations the US (30%), Europe (20%), and China (10%),” he added. 7/23
Mathew Biegler sees the Phase 2 trial in AML supporting a streamlined path to market, while multiple readouts from ongoing academic-sponsored trials could de-risk MultiTAA in additional indications.
Steve Brozak comments, following the reported encouraging news for the treatment of two high-mortality cancers, "AML has been designated as MRKR’s lead indication. The company expects to finalize the protocol for a confirmatory Phase 3 clinical trial by end of 2Q-2019 and to submit an IND in 3Q, with the first patient enrolled by end of year.
Market Data 
Markets 
AI
